Process for the preparation of aerosol compositions

Abstract: There is provided inter alia a process for preparing a pharmaceutical aerosol formulation for use in the treatment of asthma by inhalation characterised in that it consists essentially of particulate salbutamol sulphate as medicament and 1,1,1,2-tetrafluoroethane as propellant and that the formulation is free of surfactant, wherein said medicament is present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation, which process comprises dispersing the medicament in the propellant.

Description: This invention relates to a process for the preparation of aerosol formulations of use for the administration of medicaments by inhalation. The use of aerosols to administer medicaments has been known for several decades. Such aerosols generally comprise the medicament, one or more chlorofluorocarbon propellants and either a surfactant or a solvent, such as ethanol. The most commonly used aerosol propellants for medicaments have been propellant 11 (CCl 3 F) and/or propellant 114 (CF 2 CICF 2 CI) with propellant 12 (CCl 2 F 2 ). However these propellants are now believed to provoke the degradation of stratospheric ozone and there is thus a need to provide aerosol formulations for medicaments which employ so called "ozone-friendly" propellants. A class of propellants which are believed to have minimal ozone-depleting effects in comparison to conventional chlorofluorocarbons comprise fluorocarbons and hydrogen-containing chlorofluorocarbons, and a number of medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777, WO91/04011, WO91/11173, WO91/11495 and WO91/14422. These applications are all concerned with the preparation of pressurised aerosols for the administration of medicaments and seek to overcome the problems associated with the use of the new class of propellants, in particular the problems of stability associated with the pharmaceutical formulations prepared. The applications all propose the addition of one or more of adjuvants such as alcohols, alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids, polyethoxylates etc) and even conventional chlorofluorocarbon propellants in small amounts intended to minimise potential ozone damage. Thus, for example EP 0372777 requires the use of 1,1,1,2-tetrafluoroethane in combination with both a cosolvent having greater polarity than 1,1,1,2-tetrafluoroethane (e.g. an alcohol or a lower alkane) and a surfactant in order to achieve a stable formulation of a medicament powder. In particular it is noted in the specification at page 3, line 7 that "it has been found that the use of propellant 134a (1,1,1,2-tetrafluoroethane) and drug as a binary mixture or in combination with a conventional surfactant such as sorbitan trioleate does not provide formulations having suitable properties for use with pressurised inhalers". Surfactants are generally recognised by those skilled in the art to be essential components of aerosol formulations, required not only to reduce aggregation of the medicament but also to lubricate the valve employed, thereby ensuring consistent reproducibility of valve actuation and accuracy of dose dispensed. Whilst WO91/11173, WO91/11495 and WO91/14422 are concerned with formulations comprising an admixture of drug and surfactant, WO91/04011 discloses medicinal aerosol formulations in which the particulate medicaments are pre-coated with surfactant prior to dispersal in 1,1,1,2-tetrafluoroethane. WO92/08447 discloses formulations comprising a drug which is surface coated with a surfactant and a hydrofluorocarbon propellant. WO91/11496 discloses use of HFA227 as an alternative propellant optionally in admixture with another propellant gas. US3,320,125 discloses CFC-containing pharmaceutical aerosol formulations in which use of sorbitan trioleate is avoided by use of propellant 11 at a concentration of 5-50%. We have now surprisingly found that, in contradistinction to these teachings, it is in fact possible to obtain satisfactory dispersions of certain medicaments in fluorocarbon or hydrogen-containing chlorofluorocarbon propellants such as 1,1,1,2-tetrafluoroethane without recourse to the use of any surfactant or cosolvent in the composition, or the necessity to pre-treat the medicament prior to dispersal in the propellant. There is thus provided in one aspect of the invention a process for preparing a pharmaceutical aerosol formulation for use in the treatment of asthma by inhalation characterised in that it consists essentially of particulate salbutamol sulphate as medicament and 1,1,1,2-tetrafluoroethane as propellant and that the formulation is free of surfactant, wherein said medicament is present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation, which process comprises dispersing the medicament in the propellant. By "free of surfactant" is meant formulations which contain no significant amounts of surfactant, for example less that 0.0001% by weight of the medicament. There is also provided a process for preparing a pharmaceutical aerosol formulation for use in the treatment of asthma by inhalation characterised in that it consists of particulate salbutamol sulphate and 1,1,1,2-tetrafluoroethane wherein said salbutamol sulphate is present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation, which process comprises dispersing the salbutamol sulphate in the 1,1,1,2-tetrafluoroethane. The particle size of the particulate (e.g. micronised) medicament should be such as to permit inhalation of substantially all of the medicament into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and preferably in the range 1-10 microns, e.g. 1-5 microns. The propellant for use in the invention is 1,1,1,2-tetrafluoroethane which has a sufficient vapour pressure to render it effective as a propellant. It is desirable that the formulations prepared according to a process of the invention contain no components which may provoke the degradation of stratospheric ozone. In particular it is desirable that the formulations are substantially free of chlorofluorocarbons such as CCl 3 F, CCl 2 F 2 and CF 3 CCl 3 . Further, formulations which are substantially free of volatile adjuvants such as a saturated hydrocarbon, for example propane, n-butane, isobutane, pentane and isopentane, or a dialkyl ether for example dimethyl ether, are preferred. The formulations prepared according to a process of the invention may be prepared by dispersal of the medicament in the propellant in an appropriate container, e.g. with the aid of sonication. The process is desirably carried out under anhydrous conditions to obviate any adverse effects of moisture on suspension stability. The formulations prepared according to a process of the invention form weakly flocculated suspensions on standing but, surprisingly, these suspensions have been found to be easily redispersed by mild agitation to provide suspensions with excellent delivery characteristics suitable for use in pressurised inhalers, even after prolonged storage. Avoiding the use of formulation excipients e.g. surfactants, cosolvents etc in the aerosol formulations prepared according to the process of the invention is also advantageous since the formulations may be substantially taste and odour free, less irritant and less toxic than conventional formulations. The chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations prepared according to a process of the invention may be determined by techniques well known to those skilled in the art. Thus, for example, the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product. Physical stability data may be gained from other conventional analytical techniques such as, for example, by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis. The particle size distribution of the aerosol formulations prepared according to a process of the invention is particularly impressive and may be measured by conventional techniques, for example by cascade impaction or by the "Twin Impinger" analytical process. As used herein reference to the "Twin Impinger" assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A" as defined in British Pharmacopaeia 1988, pages A204-207, Appendix XVII C. Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated. As used herein reference to "respirable fraction" means the amount of active ingredient collected in the lower impingement chamber per actuation expressed as a percentage of the total amount of active ingredient delivered per actuation using the twin impinger method described above. The formulations prepared according to a process of the invention have been found to have a respirable fraction of 20% or more by weight of the medicament, preferably 25 to 70%, for example 30 to 60%. The formulations for use in the invention may be filled into canisters suitable for delivering pharmaceutical aerosol formulations. Canisters generally comprise a container capable of withstanding the vapour pressure of the propellant such as a plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve. The metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DF10, DF30, DF60), Bespak plc, UK (e.g. BK300, BK356) and 3M-Neotechnic Ltd, UK (e.g. Spraymiser™). Conventional bulk manufacturing methods and machinery well known to those skilled in the art of pharmaceutical aerosol manufacture may be employed for the preparation of large scale batches for the commercial production of filled canisters. Thus, for example, in one bulk manufacturing method a metering valve is crimped onto an aluminium can to form an empty canister. The particulate medicament is added to a charge vessel and liquified propellant is pressure filled through the charge vessel into a manufacturing vessel. The drug suspension is mixed before recirculation to a filling machine and an aliquot of the drug suspension is then filled through the metering valve into the canister. Typically, in batches prepared for pharmaceutical use, each filled canister is check-weighed, coded with a batch number and packed into a tray for storage before release testing. Each filled canister is conveniently fitted into a suitable channelling device prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient. Suitable channelling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient e.g. a mouthpiece actuator. Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation or "puff', for example in the range of 10 to 5000 microgram medicament per puff. Administration of medicament may be indicated for the treatment of mild, moderate or severe acute or chronic symptoms or for prophylactic treatment. It will be appreciated that the precise dose administered will depend on the age and condition of the patient, and the frequency of administration and will ultimately be at the discretion of the attendant physician. Typically, administration may be one or more times, for example from 1 to 8 times per day, giving for example 1,2,3 or 4 puffs each time. Suitable daily doses, may be, for example in the range 100 to 1000 microgram of salbutamol depending on the severity of the disease. Thus, for example, each valve actuation may deliver 100 microgram salbutamol. Typically each filled canister for use in a metered dose inhaler contains 100, 160 or 240 metered doses or puffs of medicament. Asthma can be treated by the administration by inhalation of an effective amount of a formulation as herein described. The following non-limitative Examples serve to illustrate the invention. Example 1 Micronised salbutamol sulphate (31.7mg) was weighed into a clean, dry, plastic-coated glass bottle and 1,1,1,2-tetrafluoroethane (18.2g) was added from a vacuum flask. The bottle was quickly sealed with a blank aluminium ferrule. The resulting aerosol contained 0.174% w / w salbutamol sulphate. Example 2 Micronised salbutamol sulphate (31.7mg) was weighed directly into each of 4 open aluminium cans. 1,1,1,2-Tetrafluoroethane (18.2g) was added to each can from a vacuum flask and a metering valve was then crimped into place. Each filled canister was then shaken in an ultrasonic bath for 5 minutes. The resulting inhalers contained 31.7mg salbutamol sulphate and delivered 100 microgram salbutamol per actuation.

Claims: A process for preparing a pharmaceutical aerosol formulation for use in the treatment of asthma by inhalation characterised in that it consists essentially of particulate salbutamol sulphate as medicament, and 1,1,1,2-tetrafluoroethane as propellant, and that the formulation is free of surfactant, wherein said medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation, which process comprises dispersing the medicament in the propellant. A process for preparing a pharmaceutical aerosol formulation for use in the treatment of asthma by inhalation characterised in that it consists of particulate salbutamol sulphate and 1,1,1,2-tetrafluoroethane, wherein said salbutamol sulphate is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation, which process comprises dispersing the salbutamol sulphate in the 1,1,1,2-tetrafluoroethane. A process for preparing a pharmaceutical aerosol formulation according to claim 2 wherein salbutamol sulphate is present in the formulation at a concentration of 0.174% w/w. A process for preparing an aluminium can closed with a metering valve containing a pharmaceutical aerosol formulation for use in the treatment of asthma by inhalation characterised in that the process comprises (a) preparing a formulation which consists of particulate salbutamol sulphate and 1,1,1,2-tetrafluoroethane, wherein said salbutamol sulphate is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation and (b) filling the formulation into an aluminium can which is closed with a metering valve. A process according to claim 4 wherein in step (a) the formulation is prepared by dispersing the salbutamol sulphate in the 1,1,1,2-tetrafluoroethane. A process according to claim 4 or claim 5 which comprises (a) crimping a metering valve onto an aluminium can to form an empty canister and (b) filling an aliquot of suspension of particulate salbutamol sulphate in 1,1,1,2-tetrafluoroethane through the metering valve into the canister. A process according to claim 4 which comprises: (a) crimping a metering valve onto an aluminium can to form an empty canister; (b) adding particulate salbutamol sulphate to a charge vessel and pressure filling liquefied 1,1,1,2-tetrafluoroethane through the charge vessel into a manufacturing vessel to form a drug suspension; (c) mixing the drug suspension before recirculation to a filling machine; and (d) filling an aliquot of the drug suspension through the metering valve into the canister.

Inventors: MARRIOT RACHEL ANN, TAYLOR ANTHONY JAMES, WYATT DAVID ANDREW, MARRIOT, RACHEL, ANN, TAYLOR, ANTHONY, JAMES, WYATT, DAVID, ANDREW, Taylor, Anthony, James, c/o GlaxoSmithkline, Wyatt, David, Andrew, c/o GlaxoSmithkline
Applicants: GLAXO GROUP LTD, GLAXO GROUP LIMITED
Application year: 1992
Main classification: A61K9
IPC codes: A61K45, A61K31, A61K9, A61P11, A61M15, A61K47